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Summary The results of the Swedish two-county study are analysed with respect to tumour size, nodal status
and malignancy grade, and the relationship of these prognostic factors to screening and to survival. It is
shown that these factors can account for much of the differences in survival between incidence screen detected,
interval and control group cancers but to a lesser extent for cancers detected at the prevalence screen where
length bias is greatest. Furthermore, examination of the relationships among the prognostic factors and mode
ofdetection indicates that malignancy grade, as a measure ofinherent malignant capacity, evolves as a tumour
grows. The proportion of cancers with poor malignancy grade is several fold lower for cancers of diameter less
than 15 cm than for cancers greater than 30 cm, independent of the length bias of screening. The implications
of these findings for screening frequency are briefly discussed.
It has been shown that mortality from breast cancer can be
reduced by mass screening using mammography (Shapiro et
al., 1982; Tabar et al., 1985), a reduction resulting from
earlier diagnosis. The natural history of breast cancer, how-
ever, is clearly heterogeneous, with substantial variation
among tumours in their malignant potential, rate of growth
and prognosis. Further, little is known of the rate at which
prognosis deteriorates as a tumour develops or conversely
how prognosis improves as the time of diagnosis is advanced.
It is known that screening does reduce rates of larger
tumours and of metastases (Fagerberg et al., 1985; Tabar et
al., 1987). Moreover, these factors affect survival, as does
malignancy grades. However, these relationships have not
been fully quantified in a screening context, so the
mechanism whereby screening can reduce mortality is not
fully understood. The purpose of the present paper is to
examine, using the results of the Swedish two-county study:
(1) the relationships among the prognostic factors: tumour
size, nodal involvement and malignancy grade;
(2) the change in these factors brought about by screening;
(3) the extent to which the change in the distributions of
prognostic factors achieved by screening can account for
the mortality reduction;
(4) whether malignancy grade is affected by an advance in
the time of diagnosis or whether it is an inherent charac-
teristic; and
(5) whether the prognostic variables listed above, or a subset
of them, can be used as surrogate variables for the final
endpoint, breast cancer mortality, i.e. can future mor-
tality be accurately predicted using these variables, for
screened and unscreened populations?
Subjects and methods
The data is from the Swedish two-county trial of mammog-
raphic screening for breast cancer, and is confined to women
aged 40-69 at entry, among whom compliance was good. In
this age group, 66,741 women were invited to regular mam-
mographic screening and 48,678 women were not (Tabar et
al., 1989). Principal results and further details of the trial are
given elsewhere (Tabar et al., 1985, Fagerberg et al., 1985).
Screening in the control group began in the year of the first
publication of the results with respect to mortality. The
breast cancers included in the present study were those diag-
nosed between the date of entry to the trial and the date at
which the control group was invited to screening. Tumours in
situ were not included. The total number of breast cancer
cases thus considered was 1,582.
Follow-up for breast cancer mortality for this analysis
terminated on 31st December 1990, with an average follow-
up period since randomisation of 11 years. Deaths from
causes other than breast cancer were treated as censored
observations in the survival analysis. The criteria for deter-
mining cause of death are given by Tabar et al. (1989).
Tumour size was determined histologically, and was
available for all but four cases. Axillary lymph nodes were
histologically examined in 1499 cases (95%) and malignancy
grade determined in 1369 (87%). For brevity we use the term
'node status' to refer to the factor with three classes at time
of diagnosis: nodes negative; nodes positive without distant
metastases; and distant metastases. Malignancy grade (Bloom
& Richardson, 1957; Scarff & Torloni, 1968) was determined
by one pathologist in each county, but as results demon-
strate, there were differences between the two counties in
proportions of grades 1, 2 and 3, probably reflecting subjec-
tivity in classification of tumour grade rather than a
difference in the two tumour populations. No such
differences were observed between counties for tumour size
or node status.
Statistical analysis of associations among tumour charac-
teristics was performed using log-linear modelling and logis-
tic regression (Aitkin et al., 1989). These methods yield
likelihood ratio (deviance) chi-squared tests for significance
of associations and odds ratio estimates of relative risks (for
example of being nodes positive for given grade relative to
grade 1). Survival analysis was performed using proportional
hazards regression (Cox, 1972).
Mode of detection in the study group was categorised as
detected at the prevalence (first) screening test, at a later
screening test, in the interval between screening tests, or in a
woman who refused screening.
For some purposes, cancers among the refusers and inter-
val cancers are combined with screen-detected cancers,
excluding the prevalence screen, to form a set of incident
tumours in the study group which approximately corresponds
to the incident tumours arising clinically in the control
group. If a screening test is of relatively high sensitivity, then
those cancers diagnosed in the period from immediately after
a screening test to immediately after a subsequent screening
test form a set of tumours from which length bias has been
removed (Day et al., 1984). If this group of cancers is
augmented with those occurring in the refusers, then the
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resulting 'unbiased set' can be compared with the set of
cancers occurring in the control arm during a corresponding
time period; the two sets of cancers are basically equivalent
except that the former have been diagnosed earlier. Their
comparison allows one to assess the effect ofearlier diagnosis
on tumour size, nodal involvement and malignancy grade,
without distortion of length bias.
Results
The relationship between size, nodal status, malignancy grade
anddetection mode
Table I presents the univariate distribution for the three
prognostic variables, by mode of detection and for malig-
nancy grade by county. The malignancy grade distribution
clearly varies by county. All three prognostic variables, as
expected, are significantly related to detection mode, being
more favourable among screen detected cancers; cancers
among refusers tend to have poor malignancy grade, to be
very large and to have distant metastases.
The relationship between the three prognostic variables has
been examined in two ways. First, we have considered the
proportion of cancers with positive nodes in relation to the
size and malignancy grade of the primary tumours, i.e. the
probability of dissemination as determined by the charac-
teristics of the primary tumour. Table Ila and Ilb cross-
tabulate the proportion node positive with size and grade; a
strong relationship with both is evident. Grade and size are
also closely related (Table III), so a logistic regression was
performed of proportion node positive against size, grade,
age, dectection mode and county as shown in Table IV. The
major factor is clearly tumour size, athough there was a
moderate significant residual effect of grade. Detection mode
remained significant, with an appreciably lower proportion of
node positive cancers among the screen detected, particularly
cancers detected at later screens. Interval and control group
cancers performed similarly. There was no indication that the
relative effect of malignancy grade on dissemination varied
with the size of the tumour.
The second way in which the interrelationships of the
Table II Percentage ofinvasive cancers with nodes positive or distant
metastases by tumour size and grade
(a) Tumour size
(mm) 1-9 10-1415-1920-2930-49 50+ Overall
Percent positive or
distant metastases 5.8 18.5 28.2 42.8 68.5 82.4 34.9
Total cases 226 319 301 360 200 91 1497
(b) Grade 1 2 3 Overall
Percent positive or
distant metastases 11.4 30.0 47.5 33.1
Total cases 297 466 540 1303
TableII Percentagedistribution ofmalignancygradeby tumoursize
and county
(a) Kopparberg
Tumour size (mm)
Grade 1-9 10-1415-1920-2930-49 50+ Overall
Grade 1 35.6 27.5 16.3 9.6 5.9 6.8 18.2
Grade 2 49.0 43.7 43.4 45.2 36.5 27.3 42.8
Grade 3 15.4 28.8 40.3 45.2 57.6 65.9 39.0
Total cases 104 142 129 155 85 44 659
(b) 6stergotland
Grade 1 48.6 39.7 25.2 13.7 10.5 0.0 26.4
Grade 2 35.1 34.6 32.5 25.1 16.3 33.3 29.6
Grade 3 16.3 25.7 42.3 61.2 73.2 66.7 44.0
Total cases 111 156 151 175 86 30 709
prognostic factors has been examined is in terms of the
primary tumour itself, the relationship between size and
malignancy. The proportion with the worst malignancy grade
(grade 3 tumour) was regressed (logistic regression) against
size, detection mode, age and county, as shown in Table Va.
Size again is the overwhelmingly dominant factor. There is
some residual effect, however, of detection mode, with inter-
val cancers and especially cancers in the refusers displaying a
higher proportion of poor grade cancers than would be
predicted on the basis of size. The poor grade of interval
cancers occurs mainly in cancers less than 2 cm in diameter,
Table I Percentages ofinvasive cancers in categories ofsize, grade and node status by
detection mode
Factor/category
Size 1-9 mm
10-14 mm
15-19 mm
20-29 mm
30-49 mm
50 mm or more
Total cases
Not known
Node status
Negative
Positive
Distant metastases
Total cases
Not known
Kopparberg
Grade I
Grade 2
Grade 3
Total cases
Not known
Ostergotland
Grade I
Grade 2
Grade 3
Total cases
Not known
First
screen
26.1
29.6
19.7
14.1
6.3
4.2
284
1
78.6
20.7
0.7
271
14
25.2
37.4
37.4
139
I
44.5
27.0
28.5
137
8
Later
screens
27.2
26.4
24.0
16.5
4.8
1.1
375
1
83.9
15.5
0.6
361
15
24.2
52.7
23.1
182
1
34.2
31.0
34.8
155
38
Interval
cases
8.1
21.0
17.3
31.5
15.3
6.8
248
0
53.6
41.8
4.6
237
11
11.5
34.5
54.0
113
2
16.3
31.5
52.2
92
41
Refusals
6.2
8.6
13.6
28.4
22.2
21.0
81
0
37.5
41.7
20.8
72
9
11.1
40.7
48.1
27
2
0.0
29.0
71.0
31
21
Control
group
7.1
15.4
19.7
29.0
20.0
8.8
590
2
54.5
39.8
5.7
558
34.
12.6
42.2
45.2
199
4
19.7
29.6
50.8
294
95
Overall
15.4
21.1
20.0
23.7
13.3
6.5
1578
4
65.0
30.9
4.1
1499
83
18.2
42.7
39.1
660
10
26.4
29.6
44.0
709
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TableIV Results oflogistic regression ofprobability ofnodes positive
ordistantmetastases on age, size, grade bycounty and detection mode,
with the effect ofeach factor adjusted for all other factors
Factor/category Odds ratio (95% CI) Significance
Detection mode P = 0.0004
Control 1.00 -
First screen 0.74 (0.49, 1.10)
Subsequent screens 0.50 (0.33, 0.74)
Interval 1.27 (0.86, 1.87)
Refusers 1.37 (0.72, 2.58)
Age P =0.01
40-49 years 1.00
50-59 years 0.99 (0.67, 1.45)
60-69 years 0.65 (0.44, 0.94)
Size P<0.0001
1-9 mm 1.00 -
10-14mm 3.25 (1.58, 6.67)
15-19mm 4.84 (2.38, 9.81)
20-29mm 7.97 (3.96, 16.03)
30-49 mm 21.96 (10.41, 46.30)
50+ mm 42.99 (17.30, 106.81)
Grade by county P<0.0001
Osterg6tland
Grade 1 1.00 -
Grade 2 2.88 (1.59, 5.22)
Grade 3 3.67 (2.10, 6.42)
Kopparberg
Grade 1 1.00 -
Grade 2 1.91 (0.96, 3.76)
Grade 3 2.43 (1.23, 4.77)
TableV Results oflogistic regression ofprobabilityofgrade 3 byage,
county, tumour size and detection mode, with the effect ofeach factor
adjusted for all others
(a) Main effects
Factor/category Odds ratio (95% CI) Significance
Age P=0.2
40-49 years 1.00
50-59 years 0.84 (0.59, 1.18)
60-69 years 0.76 (0.54, 1.05)
County P= 0.03
Ostergotland 1.00
Kopparberg 0.76 (0.59, 0.98)
Detection mode P = 0.01
Control 1.00
First screen 0.92 (0.65, 1.31)
Subsequent screens 0.75 (0.54, 1.06)
Interval 1.44 (1.00, 2.07)
Refusers 1.64 (0.88, 3.02)
Size P<0.0001
1-9 mm 1.00
10-14mm 1.83 (1.13, 2.95)
15-19 mm 3.76 (2.35, 5.99)
20-29 mm 5.83 (3.67, 9.26)
30-49 mm 9.56 (5.64, 16.20)
50+ mm 9.33 (4.82, 18.05)
(b) Effect ofdetection mode by size
Twnours <20 mm Tumours 20 + mm
Detection mode Odds Odds
ratio (95% CI) ratio (95% CI)
Control 1.00 - 1.00 -
First screen 0.88 (0.55, 1.42) 1.24 (0.70, 2.18)
Later screens 1.00 (0.64, 1.55) 0.48 (0.28, 0.82)
Interval 2.13 (1.25, 3.63) 1.03 (0.63, 1.66)
Refusers 1.63 (0.56, 4.75) 1.61 (0.75, 3.43)
as indicated by a significant interaction (P= 0.04) as shown
in Table Vb.
The increase with size of the proportion of malignancy
grade three tumours could arise in two ways. One explana-
tion would require that malignancy grade deteriorates as a
tumour grows. An alternative explanation would invoke
length bias, i.e. malignancy grade remains unchanged as a
tumour grows but grade 1 or 2 tumours grow more slowly
and hence provide greater opportunity for diagnosis at a
smaller size. One can test which hypothesis is correct by
comparing two sets of tumours from which length bias has
been largely removed, namely the control group and the
'unbiased set' described in the methods section, consisting of
study group cancers less those diagnosed at the prevalence
screen. The distribution by size and malignancy grade of
these two sets of cancers is given in Table VI. The 'unbiased
set' is smaller in size, indicating the effect of screening, but
also more favourable in malignancy grade. If one applies the
joint distribution of size and malignancy grade seen in the
control group to the size distribution observed in the 'un-
biased set', one obtains an expected malignancy grade dis-
tribution for the 'unbiased set'. As can be seen from Table
VI, this expected distribution corresponds closely to the
observed, demonstrating that the difference in malignancy
grade distribution between the two groups of cancers can be
accounted for solely in terms of size (and confirming the
absence of length bias). This comparison indicates strongly
that malignancy grade worsens with increasing size in Table
V and by the changing proportion of grade 1 and 3 cancers
seen in Table III.
Survival in terms ofsize, nodal status, malignancy grade and
detection mode
Figure 1 displays survival by detection mode. R-efusers have
particularly poor survival. Interval cancers are similar to, in
fact do slightly better than, cancers in the control group. The
screen detected cancers as expected have much better sur-
vival, the survival of those detected at the prevalence screen
and those detected at later screens being almost indistinguish-
able. Univariate proportional hazards regression analysis
gives the results shown in Table VII, for the three prognostic
tumour characteristics and for detection mode.
The primary question that has been investigated is the
extent to which the survival differences by detection mode
can be accounted for by the characteristics of the cancers at
diagnosis. The results of a multivariate survival analysis (with
each factor's effect adjusted for all the other factors) are
given in Table VIII. All of the factors are highly significant.
Size, nodal status and malignancy grade each retain their
Table VI Comparison of size and malignancy grade distributions in
the control group and the 'unbiased' set of cancers in the screening
group
(a) Size by group
Percent with tumour size (mm) Total
Group 1-9 10-1415-1920-2930-49 50+ number
Control 6.7 15.4 20.5 29.7 19.9 7.7 492
'Unbiased' 18.7 23.3 20.8 24.0 9.2 4.0 600
Significance of difference in size between groups, P<0.0001.
(b) Grade by group and county
Percent with grade Total
County/group 1 2 3 number
Ostergotland
Control 19.7 29.6 50.7 294
'Unbiased' 24.5 30.9 44.6 278
Kopparberg
Control 12.6 42.2 45.2 199
'Unbiased' 18.6 45.3 36.0 322
Significance of difference in grade between groups, P = 0.02.
(c) Comparison ofobservedgrade in 'unbiased' set with grades expected
on the basis ofsize
Grade in 'unbiased' set Observed number Expected number
1 128 130.4
2 232 228.7
3 240 240.9
Significance of difference between observed and expected, P = 0.7.1136 S.W. DUFFY et al.
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Figure 1 Cumulative survival of breast cancer cases by detection mode. *, Screen 1; + Later screens; x Interval; 0 Refusers; x
Control.
Table VII Results ofunivariate analysis ofeffects ofdetection mode,
size, node status and grade on survival, adjusted for age and county
only
Factor/category Hazard ratio (95% CI) Significance
Detection mode P<0.0001
Control 1.00 -
First screen 0.29 (0.20, 0.44)
Later screens 0.26 (0.17, 0.38)
Interval 0.76 (0.56, 1.03)
Refusers 1.97 (1.37, 2.85)
Size P<0.0001
1-9 mm 1.00
10- 14 mm 2.03 (1.04, 3.93)
15-19mm 2.56 (1.33, 4.92)
20-29mm 6.33 (3.47, 11.54)
30-49mm 13.01 (7.12, 23.77)
50 + mm 27.89 (15.06, 51.63)
Node status P<0.0001
Negative 1.00
Positive 4.94 (3.84, 6.37)
Distant metastases 68.19 (47.15, 98.61)
Grade by county P<0.0001
Ostergotland
Grade 1 1.00
Grade 2 4.02 (1.85, 8.72)
Grade 3 10.91 (5.31, 22.38)
Kopparberg
Grade 1 1.00
Grade 2 3.75 (1.60, 8.79)
Grade 3 8.11 (3.54, 18.59)
Table VIII Results of multivariate analysis of effects of detection
mode, size, node status and grade on survival, each factor adjusted for
the others and for age and county
Factor/category Hazard ratio (95% CI) Significance
Detection mode P = 0.001
Control 1.00 -
First screen 0.57 (0.38, 0.85)
Later screens 0.66 (0.43, 1.00)
Interval 0.77 (0.54, 1.09)
Refusers 1.64 (1.06, 2.53)
Size P<0.0001
1-9 mm 1.00
10-14mm 1.48 (0.69, 3.15)
15-19mm 1.40 (0.65, 2.98)
20-29 mm 2.63 (1.28, 5.40)
30-49 mm 3.72 (1.78, 7.79)
50 + mm 4.98 (2.29, 10.79)
Node status P<0.0001
Negative 1.00
Positive 2.47 (1.85, 3.28)
Distant metastases 24.26 (14.96, 39.35)
Grade by county P<0.0001
Ostergotland
Grade 1 1.00
Grade 2 2.17 (0.98, 4.77)
Grade 3 4.10 (1.96, 8.59)
Kopparberg
Grade 1 1.00
Grade 2 2.27 (0.96, 5.35)
Grade 3 3.77 (1.62, 8.76)
univariate significance with a smooth increase in risk in the
expected direction, albeit less extreme. The change in the
relative hazards for the different detection modes is interest-
ing. Adjusted survival curves for cancers in the control
group, interval cancers and those detected at later screens are
similar. The adjusted survival curves of cancers detected at
the prevalence screen, however, are considerably better than
that in the three former groups, and that of cancers diag-
nosed among the refusers is appreciably worse. The adjusted
survival analysis was repeated using only women aged 50-69
at entry to the study, to assess the performance of the three
tumour characteristics in the age groups most frequently
targetted for screening at this moment. The results are shown
in Table IX, and are similar to those in Table VIII. There
was no significant difference between survival in incident
screen detected tumours and that in controls, nor between
survival in incident screen tumours and interval cancers,
when adjusted for the three factors grade, size and node
status.
Discussion
The two main results of this paper are first, that the
favourable prognosis of screen detected cancers (apart from
prevalence screen detected cancers) can largely be accounted
for by three tumour characteristics, diameter of the primary
cancer, nodal status and malignancy grade and second that
the malignancy of at least some cancers evolves as the cancer
grows. Adjustment for the three characteristics altered the
relative hazard ofthe incident screen tumours compared with
the controls from 0.26 to 0.66. The alteration was more
striking in those aged 50-69 at entry to the study. Taking
the first point, the three prognostic factors appear adequate
to describe survival in cancers detected at incident screens,
interval cancers and those in the control group. This result is
somewhat surprising. For given size, there is known to be
major heterogeneity in the behaviour of breast cancers,
related to varying underlying malignancy. Malignancy grade
is usually regarded as an unsatisfactory way to summarise
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TableIX Results ofmultivariate analysis ofeffects ofdetectionmode,
size, node status and grade on survival, each factor adjusted for the
others and for age and county, in women aged 50-69 at entry to the
study
Factor/category Hazard ratio (95% CI) Significance
Detection mode P = 0.002
Control 1.00 -
First screen 0.55 (0.35, 0.85)
Later screens 0.75 (0.46, 1.21)
Interval 0.63 (0.40, 0.99)
Refusers 1.56 (0.99, 2.46)
Size P<0.0001
1-9 mm 1.00 -
10-14mm 1.68 (0.67, 4.17)
15-19mm 1.62 (0.65, 4.02)
20-29mm 3.24 (1.36, 7.74)
30-49 mm 4.17 (1.70, 10.20)
50 + mm 5.87 (2.32, 14.83)
Node status P<0.0001
Negative 1.00
Positive 2.91 (2.10, 4.01)
Distant metastases 26.00 (15.44, 43.76)
Grade by county P<0.0001
Ostergotland
Grade I 1.00
Grade 2 1.89 (0.80, 4.40)
Grade 3 3.50 (1.58, 7.75)
Kopparberg
Grade 1 1.00
Grade 2 2.28 (0.80, 6.46)
Grade 3 3.51 (1.26, 9.77)
this malignant potential, since it is clearly subjective. In this
study, malignancy grade was assessed separately and inde-
pendently by one pathologist in each county. Differences
between pathologists are evident even at a crude level, as one
can see in Table I. Malignancy grade had therefore to be
considered as a separate variable in each country. Never-
theless, the relationship of malignancy grade with size and
nodal status, and with survival, was virtually the same in the
two counties. This finding strongly indicates that the two
pathologists were assessing the same underlying variable, but
scoring it differently. Furthermore this underlying variable is
an adequate description of malignant capacity of a cancer,
especially for tumours in those aged 50-69, in those cancers
not detected at first screening or in women who refused
screening. Malignancy grade is incapable of accounting fully
for the favourable survival of prevalence screen cancers.
Length bias among these cancers is a particular problem; one
would expect to detect a disproportionate number of very
slow growing cancers, the lack of malignancy of which is
beyond the capacity of a three-point malignancy grade to
express. The poor prognosis of cancers among the refusers,
even when adjusted for the three tumour characteristics, is
more difficult to understand. It is possible, however, that the
poor survival in this group may be related, in addition to
tumour characteristics, to attitudes to health care reflected in
a refusal of screening. This is borne out by the fact that the
refuser cases are also more likely than compliers to die of
causes other than breast cancer (relative hazard = 1.60).
Nevertheless, these two groups apart, one can see that for
incident cancers among the compliers in the study group
(interval plus later screens) and for cancers in the control
group, which are all incident, survival is well accounted for
by tumour size, nodal status and malignancy grade.
The survival analysis indicates that malignancy grade is a
meaningful measure of malignant capacity for incident can-
cers (i.e. groups from which serious length bias has been
removed) in both study and control groups. The results of
Tables III and VI then suggest that for many cancers this
malignant capacity increases as the tumour grows. The in-
crease in malignant capacity has been discussed by Ponten
and his co-authors (Ponten et al., 1990). They conclude that
the evidence is against it occurring, citing results that DNA
ploidy is similar in (incidence) screen detected as in clinically
detected cancers, even though the former are diagnosed on
average some 3 years earlier.
On the other hand, giving support to the possibility that
the malignant capacity of a cancer may evolve are recent
results demonstrating that many cancers display considerable
heterogeneity in terms of thymidine labelling index (TLI) and
steroid hormone receptors, and a lower degree of within
tumour heterogeneity for DNA ploidy (Meyer & Wittliff,
1991). Heterogeneity provides a potential for differential
growth rates of different cell populations in a tumour. The
situation would be greatly clarified if biochemical or genetic
measures of malignancy could be developed, demonstrably
related to survival and accounting for the effects of the
subjective measure of malignancy grade, and for which
evidence analogous to Table VI could be adduced.
The implications for breast screening ifmalignancy evolves
with tumour growth are important. It would suggest that the
benefit from screening comes not only from the smaller size
at which cancers are detected, but also from an overall
reduction in the degree of malignancy. Screening more fre-
quently would, then, in addition to reducing the number of
interval cancers, improve appreciably the prognostic charac-
teristics of the screen detected cancers.
It is interesting to note that much of the effect of size, both
its independent effect on survival and its relationship with
tumour grade, is absent if one considers only tumours greater
than 2 cm in diameter, that is, cancers which are generally
detectable clinically. Most of the size effect occurs in the
difference between these tumours and those smaller than
2 cms in diameter, when detection by mammography is of
greatest relevance. In clinically detected cancers one would
not expect to observe a major independent effect for size on
either survival (Haybittle et al., 1982) or on malignancy
grade.
Screening women over 50 years of age every 33 months
reduces breast cancer mortality by some 40% (over a 10-year
period, for the women screened). The results of this paper
suggest that more frequent screening may yield substantially
improved benefits.
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